New targeted therapy aims to control rare skin cancer in patients who failed other treatments
Disease control
Not yet recruiting
This study tests an experimental drug, VG712, in people with mycosis fungoides (a rare skin lymphoma) that has not responded to at least two prior treatments. The drug works by killing certain immune cells that drive the disease. About 386 adults will be randomly assigned to rece…
Phase: PHASE2 • Sponsor: Virogen Biotechnology Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC